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Abstract
Randomized trials of infectious disease interventions often focus on groups of connected or
potentially interacting individuals. When the pathogen of interest is transmissible between
study subjects, infection outcomes may exhibit dependence, and it can be challenging to define
and estimate the causal “direct effect” of the intervention on individuals who receive it. Two
very different paradigms guide researchers in conceptualizing this effect: a randomization design-
based perspective defines the direct effect as a contrast between the infection risk of a given
individual under treatment versus no treatment, averaged over the conditional distribution of
randomized assignments to other individuals; a structural model-based perspective defines the
direct effect as a contrast between the infection risk of a given individual under treatment versus
no treatment, with exposure to infectiousness held constant. In this paper, we show that the
design- and model-based definitions of the causal direct effect are incompatible under some
randomization designs when the outcome is contagious. In particular, design-based average
risk differences may not recover the sign of the true individualistic effect of the intervention,
even in large samples. The results suggest that widely recommended randomization designs and
estimators may provide misleading inferences about the direct effect of an intervention – such
as a vaccine – when outcomes are contagious.
Keywords: contagion, interference, probabilistic coupling, transmission model, vaccine trial
1 Introduction
Randomized trials are widely used in the evaluation of infectious disease interventions among po-
tentially interacting individuals [Halloran et al., 1997, Datta et al., 1999, Halloran et al., 2010]. For
example, randomized trials have been employed to evaluate the effects of interventions, including
vaccines, to prevent influenza [Belshe et al., 1998, Hayden et al., 2000, Welliver et al., 2001, Monto
et al., 2002], pertussis [Simondon et al., 1997], typhoid [Acosta et al., 2005], and cholera [Clemens
et al., 1986, Perez-Heydrich et al., 2014], among many other diseases. The primary effect measure
in most trials of infectious disease interventions is the “direct effect”, the effect of treatment on
the infection risk of the individual who receives it. However, when the infection is transmissible,
or contagious, between study subjects, the treatment delivered to one subject may affect the in-
fection outcome of others, via prevention of the original subject’s infection or reduction in their
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infectiousness once infected [Halloran and Struchiner, 1991, 1995]. This phenomenon – called “in-
terference” in the causal inference literature – complicates definition and estimation of intervention
effects under contagion [Halloran and Struchiner, 1995, VanderWeele and Tchetgen, 2011, Halloran
and Hudgens, 2016, Halloran et al., 2017, Ogburn et al., 2017, Ogburn, 2018]. Researchers have of-
fered definitions of the “direct effect” of an intervention in various contexts [Robins and Greenland,
1992, Pearl, 2001, Rubin, 2004], but Halloran and Struchiner [1995] offered the first formal causal
definition of the direct effect for infectious disease interventions [Tchetgen and VanderWeele, 2010].
In an influential paper, Hudgens and Halloran [2008] proposed a randomization design and
a definition of the causal direct effect of an intervention under interference in a clustered study
population. Informally, Hudgens and Halloran [2008] define the direct effect as a contrast between
the rate of infection for an individual under treatment versus no treatment, averaged over the
conditional distribution of treatments to others in the same cluster [Sa¨vje et al., 2017]. This
approach is nonparametric in the sense that it does not require structural assumptions about how
the joint distribution of treatment in clusters affects the risk of infection for individuals. The direct
effect estimand introduced by Hudgens and Halloran [2008] has been applied in empirical analyses
of randomized vaccine trials [e.g. Perez-Heydrich et al., 2014].
In a starkly different strain of work, researchers have proposed structural models of infectious
disease outcomes that formalize common ideas about the mechanism, or dynamics, of transmission
in groups [Becker, 1989, Anderson and May, 1992, Andersson and Britton, 2000]. Many structural
transmission models represent the individual risk (or hazard) of infection as an explicit function
of individual treatments and possibly other covariates [Rhodes et al., 1996, Longini Jr et al., 1999,
Auranen et al., 2000, O’Neill et al., 2000, Becker et al., 2003, Becker and Britton, 2004, Cauchemez
et al., 2004, 2006, Becker et al., 2006, Yang et al., 2006, Kenah, 2013, 2014, Morozova et al., 2018].
Structural models can be useful in both observational and randomized trials because they posit an
explicit regression-style relationship linking covariates and infection outcome. The “direct effect”
is represented by a contrast between the rate (or hazard) of infection under treatment versus no
treatment, while holding exposure to infectiousness constant [Halloran et al., 1991, 1997, Golm
et al., 1999, O’Hagan et al., 2014]. In this work, the per-exposure direct effect is sometimes called
the “susceptibility effect” or the “vaccine effect on susceptibility”.
What is the relationship between design- and structural model-based definitions of the direct
effect? Randomization ensures that on average, treated and untreated individuals do not vary
systematically in their baseline characteristics. However, even when treatment is randomized,
exposure to infection can be different among treated and untreated individuals during the study.
Researchers have warned that this differential exposure can confound estimates of the “direct effect”
of the intervention [Halloran et al., 1991, Halloran and Struchiner, 1991, Struchiner et al., 1994,
Halloran and Struchiner, 1995, Halloran et al., 2010, Kenah, 2014, Morozova et al., 2018], but
the relationship between the randomization design and the disease transmission process remains
obscure [van Boven et al., 2013, O’Hagan et al., 2014]. In work evaluating the relationship between
the risk ratio and the exposure-conditioned effect in a vaccine trial, Struchiner and Halloran [2007,
page 184] write “The question of interest [. . . ] is to what extent, even under randomization, does
the estimated efficacy measure the effect of interest?” In particular, do contrasts of expected
infection outcomes between treated and untreated subjects, as proposed by Hudgens and Halloran
[2008], estimate the per-exposure direct effect of the intervention when the population is clustered,
treatment is randomized, and outcomes are contagious?
In this paper, examine the meaning of the “direct effect” defined by Hudgens and Halloran
[2008] using a general conception of infectious disease transmission in a study of potentially inter-
acting individuals within clusters. First, we define three common randomization designs – Bernoulli,
block, and cluster randomization – and describe a general transmission model of infectious disease
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transmission in clusters that accommodates individually varying susceptibility to infection, infec-
tiousness, and exogenous source of infection. We then introduce averaged contrasts of potential
infection outcomes defined formally as the “direct effect” by Hudgens and Halloran [2008]. We
show that under some forms of randomization, these contrasts may not recover the direction (or
sign) of the true susceptibility effect of the intervention on the individual who receives it. The
results are derived using a probabilistic coupling argument that reveals stochastic dominance rela-
tions between infection outcomes under different treatment allocations. These results substantially
sharpen the claims of Halloran et al. [1991] and Struchiner and Halloran [2007], and generalize bias
results for clusters of size two [Halloran and Hudgens, 2012, Morozova et al., 2018].
2 Setting
2.1 Randomization designs for clustered subjects
Consider a sequence of clusters i = 1, . . . , N where the number of subjects in cluster i is ni. A
randomization design is a probability distribution that assigns the joint binary treatment vector
xi = (xi1, . . ., xini) within and across clusters.
Definition 1 (Bernoulli randomization). The treatment mechanism is Bernoulli randomized if for
every cluster i, the joint allocation xi = (xi1, . . . , xini) has probability Pr(Xi = xi) =
∏ni
j=1 p
xij (1−
p)1−xij for some probability p.
Definition 2 (Block randomization). The treatment mechanism is block-randomized if for every
cluster i, the joint allocation xi = (xi1, . . . , xini) has probability Pr(Xi = xi) =
(
ni
mi
)−1
1
{∑ni
j=1 xij = mi
}
where 0 < mi = bpnic for some probability p > 1/mini ni.
Definition 3 (Cluster randomization). The treatment is cluster randomized if for each cluster i,
either all members of the cluster are treated, or all are untreated with probability 0 < p < 1. That
is, Pr(Xi = (1, . . . , 1)) = p and Pr(Xi = (0, . . . , 0)) = 1− p for each cluster i independently.
2.2 Structural model of infectious disease transmission
We present a general structural model of infectious disease transmission based on the canonical
stochastic susceptible-infective epidemic process [Becker, 1989, Andersson and Britton, 2000, Diek-
mann et al., 2012]. Consider a cluster i of size ni and let Tij be the random infection time of
subject j. Let Yij(t) = 1{Tij < t} be the left-continuous indicator of prior infection. A subject j
is called susceptible at time t if Yij(t) = 0 and infected if Yij(t) = 1. The joint treatment vector
xi = (xi1, . . . , xini) is allocated at baseline, t = 0. Suppose the hazard of infection experienced by
a susceptible individual j in cluster i at time t is
λij(t) = e
xijβ+ηij
(
α+
ni∑
k=1
Yik(t)e
xikγ+ξik
)
(1)
where ηij is an individualistic susceptibility coefficient for subject j, ξik is an individualistic in-
fectiousness coefficient for subject k, and α is the force of infection from outside the cluster. The
sum over k in (1) does not include k = j because j cannot infect themselves: Yij(t) = 0 when-
ever this hazard is positive. Variations on the continuous-time hazard model (1) have been used
to model sources of disease transmission and for estimation of covariate effects on infection risk
[Rhodes et al., 1996, Auranen et al., 2000, Cauchemez et al., 2004, 2006, Kenah, 2013, 2014, Tsang
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Figure 1: Illustration of the infectious disease transmission process and hazards (1) in a cluster i
of size ni = 4, where individuals 1 and 3 are treated (gray shading), while 2 and 4 are not. Circles
indicate susceptible individuals, and stars indicate infected individuals; arrows represent risk of
transmission. At time ti2, subject 2 becomes infected, and thereafter transmits infection risk to 1,
3, and 4. Subsequently 3 becomes infected, and 1 and 4 are exposed to infection risk from both 2
and 3. The magnitude of this infection risk is related to the treatment status of the susceptible and
infectious individuals. At bottom, hazards of infection λij(t) are shown over time for each subject.
The “susceptibility” effect of treatment is β, and the “infectiousness” effect is γ.
et al., 2018], and as a conceptual model to evaluate the properties of risk ratios under contagion
[Morozova et al., 2018]. Figure 1 shows a schematic illustration of the transmission hazard model
(1) for a cluster i of size ni = 4 in which two subjects are treated.
We will sometimes refer to the quantity in parentheses in (1) as the “exposure to infection”
experienced by a susceptible subject at time t. The direct, or “susceptibility”, effect of the treatment
xij on the susceptible subject j who receives it is β [Halloran et al., 1991, Halloran and Struchiner,
1991, O’Hagan et al., 2014]. It follows that eβ is the proportion change in the instantaneous
infection risk experienced by j due to treatment, at every time t, regardless of their exposure to
infectiousness; in other words, β is a log hazard ratio with exposure to infection held constant.
The “infectiousness effect” of the treatment xik assigned to k, on the susceptible subject j, is γ
[Halloran et al., 1997]. As in Hudgens and Halloran [2008], the structural transmission model
(1) obeys “partial interference” [Sobel, 2006, Halloran and Struchiner, 1991, 1995]: the infection
outcome for subject j in cluster i may depend on treatments and infection outcomes of other
individuals in cluster i, but does not depend on subjects in clusters other than i.
Suppose infections within cluster i occur at times Ti1 = ti1, . . ., Tini = tini . Fix a study time
T > 0 and let yi(t) = (yi1(t), . . ., yini(t); 0 ≤ t ≤ T ) be the collection of infection indicator
functions for subjects in cluster i. Define t∗ij = min(tij , T ). The likelihood of a realization yi(t) in
cluster i is
Li(yi(t)) =
ni∏
j=1
[λij(tij)]
yij(T ) exp
[
−
∫ t∗ij
0
λij(t) dt
]
(2)
where λij(t) is given by (1).
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2.3 Definition of the “direct effect”
We now introduce potential outcome notation [Rubin, 2005] that will be used to define causal effects.
Let xi = (xi1, . . . , xini) be a joint treatment allocation to cluster i. Let Tij(xi) be the stochastic
potential infection time of j under the joint treatment allocation xi. Let Yij(t,xi) = 1{Tij(xi) < t}
be the corresponding stochastic potential infection outcome of subject j at time t. Define the
expected individual infection outcome as Y ij(t,xi) = E[Yij(t,xi)] where expectation is with respect
to the stochastic infection process defined by (1). Let X n = {0, 1}n be the set of all binary vectors
of n elements. Following notation introduced by Hudgens and Halloran [2008], we will sometimes
write the joint treatment allocation in cluster i as xi = (xij ,xi(j)), where xij is the treatment to
subject j, and xi(j) is the vector of treatment assignments to subjects other than j in cluster i.
We define causal estimands by comparing average infection outcomes under different treat-
ment allocations to the cluster. These definitions are taken, with minor changes in notation, from
Hudgens and Halloran [2008]. Define the individual average potential outcome as
Y ij(t, x) =
∑
xi(j)∈Xni−1
Y ij(t, x,xi(j)) Pr(Xi(j) = xi(j)|Xij = x). (3)
Informally, Y ij(t, x) is the individual infection outcome under xij = x, averaged over the conditional
distribution of treatments to the other individuals in cluster i. Define the cluster average potential
outcome as Y i(t, x) = n
−1
i
∑ni
j=1 Y ij(t, x), and the population average potential outcome as Y (t, x) =
N−1
∑N
i=1 Y i(t, x). Hudgens and Halloran [2008] propose contrasts of these potential outcomes
as causal estimands, which we rewrite in slightly different form. Define the individual average
risk difference as RDij(t) = Y ij(t, 1) − Y ij(t, 0), the cluster average risk difference as RDi(t) =
n−1i
∑ni
j=1RDij(t), and the population average risk difference as RD(t) = N
−1∑N
i=1RDi(t).
Researchers have raised concerns about the estimands defined by Hudgens and Halloran [2008].
VanderWeele and Tchetgen [2011] point out that the risk difference RD(t) may not be interpretable
as a direct effect under block randomization, because it compares the outcome of a treated individual
whose cluster contains mi − 1 others treated with an untreated individual whose cluster contains
mi others treated. Sa¨vje et al. [2017] call RD(t) the “average distribution shift effect” because
it “captures the compound effect of changing a unit’s treatment and simultaneously changing the
experimental design”. Beyond these definitional criticisms of RD(t), questions remain about which
features of the infectious disease transmission process it measures. The infection hazard model (1)
describes the instantaneous risk of infection for subject j in cluster i, as a function of the treatment
allocation xi. The parameter β is interpreted as the direct, or susceptibility, effect of the treatment.
Do the average risk difference measures RDij(t), RDi(t), and RD(t) above recover useful features
of the true per-exposure direct effect β under the hazard model (1)? For example, if the treatment
x is a vaccine that helps prevent infection in the person who receives it (β < 0), investigators
conducting a randomized trial might like to know whether the population average estimand has
the same property, RD(t) < 0. This question is central to the individualistic causal interpretation
of marginal, or population average, contrasts in infectious disease epidemiology.
3 Results
3.1 RD under the null hypothesis of no direct effect
If the risk difference is to serve as a useful estimand for researchers interested in learning about the
causal direct effect of the intervention, we should expect that RDij(t) = 0 when β = 0, since the
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treatment has no effect on the infection risk of an individual who receives it. We begin by studying
the properties of the average individual risk difference RDij(T ) under the three randomization
designs. We assume that the exogenous (community) force of infection α is positive, and T > 0 is
a follow-up time at which infection outcomes are measured, so that at least one infection in each
cluster arises with positive probability.
Bernoulli randomization gives concordance between β = 0 and the risk difference.
Proposition 1 (RD under Bernoulli randomization). Suppose β = 0 and treatment assignment is
Bernoulli randomized. Then RDij(T ) = 0.
In contrast, the risk difference has the opposite sign as the infectiousness effect γ when β = 0 under
block randomization.
Proposition 2 (RD under block randomization). Suppose β = 0 and treatment assignment is
block-randomized. If γ < 0 then RDij(T ) > 0; if γ = 0 then RDij(T ) = 0; and if γ > 0 then
RDij(T ) < 0.
The risk difference has the same sign as γ when β = 0 under cluster randomization.
Proposition 3 (RD under cluster randomization). Suppose β = 0 and treatment assignment is
cluster randomized. If γ < 0 then RDij(T ) < 0; if γ = 0 then RDij(T ) = 0; and if γ > 0 then
RDij(T ) > 0.
Proposition 1 can be proved directly.
Proof of Proposition 1. We establish a slight extension of the potential outcome notation. Let
xij and xik be treatments allocated to j and k respectively, and let xi(j,k) be the treatments
allocated to all other subjects. We may write the potential outcome of k under this allocation as
Yik(t, xik, xij ,xi(k,j)). When β = 0 and Yij(t, xij ,xi(j)) = 0, the random hazard of infection to j
under treatment xi = (xi1, . . . , xini) is given by
λij(t, xij ,xi(j)) = e
ηij
(
α+
ni∑
k=1
Yik(t, xik, xij ,xi(k,j))e
xikγ+ξik
)
.
But since Yij(t, xij ,xi(j)) = 0 whenever this hazard is positive, the distribution of Yik(t, xik, xij ,xi(k,j))
in this expression is invariant to the value of xij . In other words, xij cannot affect the outcome of
subject k, except via infection of j. Therefore when β = 0 and j is uninfected, the hazard functions
λij(t, 1,xi(j)) and λij(t, 0,xi(j)) have identical distribution. It follows that the expected infection
status of j at time T under xij = 1 and xi(j) is given by
Y ij(T , 1,xi(j)) = 1− E
[
exp
[
−
∫ T
0
λij(t, 1,xi(j))dt
]]
= 1− E
[
exp
[
−
∫ T
0
λij(t, 0,xi(j))dt
]]
= Y ij(T , 0,xi(j))
where the probability and expectation operators on the right-hand side are with respect to the
infection outcomes Yik(t, xik, xij ,xi(k,j)) for k 6= j, conditional on Yij(t, xij ,xi(j)) = 0 for 0 ≤ t ≤ T
6
and Xi(j) = xi(j). Likewise, under Bernoulli randomization within cluster i, the distribution of
Xi(j) is invariant to conditioning on Xij = xij , and
Y ij(T , 1) =
∑
xi(j)∈Xni−1
Y ij(T , 1,xi(j))
∏
k 6=j
pxik(1− p)1−xik
=
∑
xi(j)∈Xni−1
Y ij(T , 0,xi(j))
∏
k 6=j
pxik(1− p)1−xik
= Y ij(T , 0),
and so RDij(T ) = 0 as claimed.
Propositions 2 and 3 compare averaged expectations of infection outcomes for subject j in cluster i.
However, computing the expectation Y ij(t, x,xi(j)) for particular values of x and xi(j) is intractable,
so an explicit comparison cannot be made analytically. Instead, we will use tools from the theory
of probabilistic coupling [den Hollander, 2012, Ross, 1996] to facilitate the comparison.
Definition 4 (Coupling). A coupling of two random variables Y 0 and Y 1 both taking values in
(Ω,F) is any pair of random variables (Y˜ 0, Y˜ 1) taking values in (Ω × Ω,F ⊗ F) whose marginals
have the same distribution as Y 0 and Y 1, i.e. Y 0
d
= Y˜ 0 and Y 1
d
= Y˜ 1.
Typically the variables Y˜ 0 and Y˜ 1 are dependent. To study the relationship of infection outcomes
under different treatment scenarios, a notion of dominance will be necessary.
Definition 5 (Stochastic dominance). The real-valued random variable Y 1 stochastically dominates
Y 0 if Pr(Y 1 < y) ≤ Pr(Y 0 < y) for all y ∈ R.
If Y 1 stochastically dominates Y 0, then E[Y 1] ≥ E[Y 0]. The following Lemma, proved by e.g.
Ross [1996, pages 409–410], provides a framework for establishing stochastic dominance through
the construction of a coupling.
Lemma 1 (Coupling and stochastic dominance). The real-valued random variable Y 1 stochastically
dominates Y 0 if and only if there is a coupling (Y˜ 0, Y˜ 1) of Y 0 and Y 1 such that Pr(Y˜ 1 ≥ Y˜ 0) = 1.
A simple corollary to this result is that if Y 1 stochastically dominates Y 0 and vice versa, the
variables are equal in distribution.
In a second preliminary lemma, we evaluate differences in potential outcomes of subject j when
j and k 6= j have opposite treatments, with other subjects’ treatments held constant. Let X nm be
the set of all binary n-vectors with m positive elements.
Lemma 2. Suppose β = 0 and let z ∈ X ni−2mi−1 and for j 6= k define x1i = (xij = 1, xik = 0,xi(jk) = z)
and x0i = (xij = 0, xik = 1,xi(jk) = z). If γ < 0 then Y ij(t,x
1
i ) > Y ij(t,x
0
i ); if γ = 0 then
Y ij(t,x
1
i ) = Y ij(t,x
0
i ); and if γ > 0 then Y ij(t,x
1
i ) < Y ij(t,x
0
i ).
In other words, when z is an allocation of treatment to subjects other than j and k, the raw risk
difference Y ij(t, 1, 0, z)− Y ij(t, 0, 1, z) has the opposite sign as γ under block randomization when
β = 0.
To prove Lemma 2, we will define a procedure for generating a dependent realization of the in-
fection outcomes under opposite treatments of subjects j and k. Then we show that this realization
constitutes a coupling of the potential infection outcomes of interest. Finally, we show that this
coupling implies a stochastic dominance relation between Y ij(t,x
1
i ) and Y ij(t,x
0
i ) whose direction
depends on the sign of γ.
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Proof of Lemma 2. Define the vectors of stochastic potential outcomes of all subjects under treat-
ments x1i and x
0
i as Yi(t,x
1
i ) =
(
Yi1(t,x
1
i ), . . . , Yini(t,x
1
i )
)
and Yi(t,x
0
i ) =
(
Yi1(t,x
0
i ), . . . , Yini(t,x
0
i )
)
.
Corresponding to these potential outcomes, we will construct two coupled outcome processes Y˜1i (t)
and Y˜0i (t) under treatment vectors x
1
i and x
0
i respectively. The order of infections in both processes
is the same, but the times of infection may be different. Let Sl and Il be the set of subjects that are
susceptible and infectious, respectively, just before the lth infection event, with S1 = {1, . . . , ni}
and I1 = ∅. Let T˜ 1il and T˜ 0il be the time of infection of subject l under treatments x1i and x0i
respectively, with T˜ 1i0 = T˜
0
i0 = 0. For each l = 1, . . . , ni in order:
1. Define the cumulative distribution functions
Fl(w) = 1− exp
−w∑
a∈Sl
eηia
α+∑
b∈Il
eγx
1
ib+ξib
 (4)
Gl(w) = 1− exp
−w∑
a∈Sl
eηia
α+∑
b∈Il
eγx
0
ib+ξib
 , (5)
where sums over empty sets are interpreted as zero.
2. Draw Ul ∼ Uniform(0, 1) and set the waiting times W˜ 1l = F−1l (Ul) and W˜ 0l = G−1l (Ul).
3. Select the next infected subject Vl = v from the set of currently uninfected subjects Sl with
probability Pr(Vl = v) = e
ηiv/
∑
a∈Sl e
ηia .
4. Set the new infection times T˜ 1iVl = T˜
1
iVl−1 +W˜
1
l and T˜
0
iVl
= T˜ 0iVl−1 +W˜
0
l , the infection outcomes
Y˜ 1iVl(t) = 1
{
T˜ 1iVl < t
}
and Y˜ 0iVl(t) = 1
{
T˜ 0iVl < t
}
, and update the sets of susceptible and
infectious subjects Sl = Sl−1 \ Vl and Il = Il−1 ∪ Vl.
This procedure produces the joint outcome functions Y˜1i (t) = (Y˜
1
i1(t), . . . , Y˜
1
ini
(t)) and Y˜0i (t) =
(Y˜ 0i1(t), . . . , Y˜
0
ini
(t)). Because the same uniform variable Ul in step 2 is used to generate both W˜
1
l
and W˜ 0l , these variables, and hence the infection times T˜
1
ij and T˜
0
ij , and outcomes Y˜
1
ij(t) and Y˜
0
ij(t),
are dependent.
We now show that the constructed variables (Y˜1i (t), Y˜
0
i (t)) constitute a coupling of the potential
infection outcomes Yi(t,x
1) and Yi(t,x
0). First, note that because Fl(w) and Gl(w) are monoton-
ically increasing in w, the random waiting time W˜ 1l = F
−1
l (Ul) has distribution function Fl(w) and
W˜ 0l = G
−1
l (Ul) has distribution function Gl(w) [Devroye, 1986]. The joint mass function of the lth
infected subject Vl and the cumulative density function of waiting time W˜
1
l to this infection is, by
construction,
Pr(Vl = v, W˜
1
l < w) =
eηiv∑
a∈Sl e
ηia
1− exp
−w∑
a∈Sl
eηia
α+∑
b∈Il
eγx
1
ib+ξib
 . (6)
Differentiating (6) with respect to w, we find that the joint likelihood of the newly infected subject
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Vl = v and the waiting time w to the lth infection is
L˜1il(v, w) = e
ηiv
α+∑
b∈Il
eγx
1
ib+ξib
 exp
−w∑
a∈Sl
eηia
α+∑
b∈Il
eγx
1
ib+ξib

= eηiv
(
α+
n∑
b=1
y˜1ib(t˜
1
iv)e
γx1ib+ξib
)
exp
[
−w
n∑
a=1
(1− y˜1ia(t˜1iv))eηia
(
α+
n∑
b=1
y˜1ib(t˜
1
iv)e
γx1ib+ξib
)]
= λ˜1iv(t˜
1
iv) exp
[
−w
n∑
a=1
(1− y˜1ia(t˜1iv))λ˜1ia(t˜1iv)
]
(7)
where λ˜1ij(t) is (1) with y˜
1
i (t) and x
1
i replacing yi(t) and xi respectively. Let L˜
1
i (y˜
1
i ) be the likelihood
of the full realization of y˜1i (t) = (y˜
1
i1(t), . . . , y˜
1
ini
(t)) with T˜1 = (t˜1i1, . . . , t˜
1
ini
), W˜1 = (w˜1i1, . . . , w˜
1
ini
),
and V˜ = (v˜1i1, . . . , v˜
1
ini
). Recall that by construction, w˜1ik = t˜
1
ivk
− t˜1vi,k−1 . The likelihood of the
constructed process is
L˜(y˜1(t)) =
n∏
k=1
λ˜1ivk(t˜
1
ivk
) exp
−wk n∑
j=1
(1− y˜1ij(t˜1ivk))λ˜1ij(t˜1ivk)

=
 n∏
j=1
λ˜1ij(t˜
1
ij)
 exp
− n∑
j=1
n∑
k=1
∫ t˜1ivk
t˜1ivk−1
(1− y˜1ij(t))λ˜1ij(t) dt

=
 n∏
j=1
λ˜1ij(t˜
1
ij)
 exp
− n∑
j=1
∫ t˜1ij
0
λ˜1ij(t) dt

= L(y˜1(t))
(8)
where L(y˜1i (t)) is the likelihood (2) of the original process. Therefore the constructed outcome
vector Y˜i(t,x
1
i ) is equal in distribution to the potential outcome vector Yi(t,x
1
i ), and it follows
that Y˜ij(t,x
1
i ) is equal in distribution to Yij(t,x
1
i ). By the same reasoning, Y˜ij(t,x
0
i ) is equal in
distribution to Yij(t,x
0
i ). Therefore by Definition 4, (Y˜ij(t,x
1
i ), Y˜ij(t,x
0
i )) is a coupling of Yij(t,x
1
i )
and Y 0ij(t,x
0
i ). We can now prove the result.
When γ = 0, Fl(w) = Gl(w) for all l and all w. Therefore T˜
1
il = T˜
0
il for all l and so Y˜
1
ij(t) = Y˜
0
ij(t)
for all t. Then Yij(t,x
1
i ) is equal in distribution to Yij(t,x
0
i ) for all t and so Y ij(t,x
1
i ) = Y ij(t,x
0
i ).
When γ < 0, note that Y˜ 1ij(t) ≥ Y˜ 0ij(t) for all t if and only if T˜ 1ij ≤ T˜ 0ij . Suppose without loss of
generality that subjects are relabeled in order of their infection in the constructed process, so the
jth infection occurs in subject j, vj = j. Likewise the kth infection occurs in subject k, so vk = k.
Two cases are of interest. First, when j < k we have x1il = x
0
il for every l ≤ j, and so Fl(w) = Gl(w)
for l ≤ j < k and all w. Therefore,
T˜ 1ij =
j∑
l=1
W˜ 1l =
j∑
l=1
F−1l (Ul) =
j∑
l=1
G−1l (Ul) =
j∑
l=1
W˜ 0l = T˜
0
ij . (9)
Second, when subject k is infected first, or k < j, we have Fl(w) = Gl(w) for l < k. However, for
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subjects r infected after k (r > k), we have
Fr(w) = 1− exp
−w ∑
a∈Sr
eηia
α+ ∑
b∈Ir
eγx
1
ib+ξib

= 1− exp
−w
∑
a∈Sr
eηia
α+ ∑
b∈Ir
b 6=k
eγx
0
ib+ξib + eξik


> 1− exp
−w
∑
a∈Sr
eηia
α+ ∑
b∈Ir
b 6=k
eγx
0
ib+ξib + eγ+ξik


= 1− exp
−w ∑
a∈Sr
eηia
α+ ∑
b∈Ir
eγx
0
ib+ξib

= Gr(w)
(10)
for all w. Therefore F−1r (Ur) < G−1r (Ur) by monotonicity of Fr(w) and Gr(w), so the constructed
infection times are
T˜ 1ij =
j∑
l=1
W˜ 1l =
j∑
l=1
F−1l (Ul) =
k∑
l=1
G−1l (Ul) +
j∑
r=k+1
F−1r (Ur)
<
k∑
l=1
G−1l (Ul) +
j∑
r=k+1
G−1r (Ur) =
j∑
l=1
W˜ 0l = T˜
0
ij .
(11)
Therefore T˜ 1ij ≤ T˜ 0ij and hence Pr(Y˜ 1ij(t) ≥ Y˜ 0ij(t)) = 1. By Lemma 1, Yij(t,x1) stochastically
dominates Y 0ij(t,x
0) for all t > 0. Because infection of subject k before subject j occurs with
positive probability, it follows that the expected values of the potential infection outcomes obey
Y ij(t,x
1) > Y ij(t,x
0). The case γ > 0 is the same as for γ < 0, with inequalities switched.
With these tools in hand, the proof of Proposition 2 is straightforward via a counting argument.
Proof of Proposition 2. First, let z be a binary vector of length ni−1 with mi−1 positive elements.
Define Pi(z) = {w ∈ {0, 1}ni−1 : (w′z,w′1) = (mi − 1,mi)} as the set of ni −mi binary vectors
w of length ni − 1 for which all positive elements of z are also positive in w, and in addition w
contains one more positive element. Using this definition, and the combinatorial identity(
ni − 1
mi
)
=
ni −mi
mi
(
ni − 1
mi − 1
)
, (12)
we can decompose a sum over allocations of mi treatments to ni − 1 subjects into a sum over
allocations of mi − 1 treatments to ni − 1 subjects, and an additional allocation of treatment to
one more, ∑
w∈Xni−1mi
Y ij(t, 0,w) =
1
mi
∑
z∈Xni−1mi−1
∑
w∈Pi(z)
Y ij(t, 0,w). (13)
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The factor 1/mi appears in the right-hand side above because there are mi allocations z for which
a given w ∈ Pi(z) is compatible; the double sum over-counts allocations by a factor of mi. Using
this fact, we expand RDij(T ) into a sum over allocations to subjects other than j,
RDij(T ) =
(
ni − 1
mi − 1
)−1 ∑
z∈Xni−1mi−1
Y ij(T , 1, z)−
(
ni − 1
mi
)−1 ∑
w∈Xni−1mi
Y ij(T , 0,w)
=
(
ni − 1
mi − 1
)−1 ∑
z∈Xni−1mi−1
Y ij(T , 1, z)− mi
ni −mi
∑
w∈Xni−1mi
Y ij(T , 0,w)

=
(
ni − 1
mi − 1
)−1 1
ni −mi
∑
z∈Xni−1mi−1
(ni −mi)Y ij(T , 1, z)− ∑
w∈Pi(z)
Y ij(T , 0,w)

=
(
ni − 1
mi − 1
)−1 1
ni −mi
∑
z∈Xni−1mi−1
∑
w∈Pi(z)
(
Y ij(T , 1, z)− Y ij(T , 0,w)
)
(14)
where the first equality follows from (3) under block randomization with mi of ni subjects treated,
the second by (12), the third by (13), and the fourth because there are ni −mi terms in the sum
over w ∈ P(z). Therefore, RDij(T ) can be expressed as a sum of contrasts between the average
outcome of j under joint treatments (1, z) and (0,w) where w is the same as z, but with one
additional treated subject. Each contrast in the last line of (14) has sign given by Lemma 2, and
the result follows.
The proof of Proposition 3 is very similar and is presented in the Appendix. Three final results
generalize the results for the individual average risk differenceRDij(T ) to the cluster and population
average risk difference estimands. The proofs, which rely only on Propositions 1, 2, and 3 and the
definitions of RDi(T ) and RD(T ), are omitted.
Corollary 1 (Cluster and population average RD under Bernoulli randomization). Suppose β = 0
and treatment assignment is Bernoulli randomized. Then RDi(T ) = 0 and RD(T ) = 0.
Corollary 2 (Cluster and population average RD under block randomization). Suppose β = 0,
treatment assignment is block randomized. If γ < 0 then RDi(T ) > 0 and RD(T ) > 0; if γ = 0
then RDi(T ) = 0 and RD(T ) = 0; and if γ > 0 then RDi(T ) < 0 and RD(T ) < 0.
Corollary 3 (Cluster and population average RD under cluster randomization). Suppose β = 0
and treatment assignment is cluster randomized. If γ < 0 then RDi(T ) < 0 and RD(T ) < 0; if
γ = 0 then RDi(T ) = 0 and RD(T ) = 0; and if γ > 0 then RDi(T ) > 0 and RD(T ) > 0.
3.2 Simulation Study
We investigate the properties of the population average risk difference as the true infectiousness
effect γ changes. The hazard of infection takes the form of (1) where the null hypothesis is β = 0
and we investigate RD(T ) as a function of γ ∈ [−2, 2]. The exogenous force of infection is α =
0.01, the individual susceptibility coefficients ηij are independent Normal(µη, σ
2
η) and infectiousness
coefficients ξij are independent Normal(µξ, σ
2
ξ ). Unless otherwise noted, the cluster size ni is 2 +
Poisson(2), the observation time is T = 10, and all subjects were uninfected at baseline, Yij(0) = 0.
The Appendix provides additional details about the simulation setting.
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Figure 2: Simulation results for RD(T ) under the null hypothesis of no direct effect β = 0,
as a function of the infectiousness effect γ, for different randomization designs and cluster size
distributions. Bernoulli randomization (black) recovers RD(T ) = 0 for any γ. Block randomization
(red) shows RD(T ) has the opposite sign as γ, and cluster randomization (blue) shows RD(T ) has
the same sign as γ.
Figure 2 shows simulation results validating the analytic derivations above. Under Bernoulli
randomization RD(T ) is zero for any γ; under block randomization it has the opposite sign as γ;
and under cluster randomization it has the same sign as γ. Figure 3 shows properties of RD(T )
as a function of γ under various epidemiologic and study design parameters, when β = 0. The
top row shows results under block randomization, and the bottom row shows results under clus-
ter randomization. The left column shows RD(T ) for increasing values of σ2, the variability of
individual-level susceptibility and infectiousness. The middle column shows how RD(T ) changes
with µξ, the average value of the individual-level infectiousness coefficient. When these values are
large and negative, few infections are transmitted by infected individuals, so the value of γ has
little effect on RD(T ), which stays near zero. When µξ is large and positive, something similar
happens: infected individuals are highly infectious even when γ < 0, and RD(T ) is near zero for a
wide range of values of γ. When µξ is near zero, the value of γ fully determines the infectiousness of
treated individuals, and RD(T ) exhibits the largest difference from zero. In the right column, we
examine the effect of changes and heterogeneity in the follow-up time T , allowing the observation
time Ti to vary between clusters. In all cases, the magnitude of the risk difference increases with
the absolute value of γ. While Propositions 1 - 3 give the sign of RD(T ) for any combination of
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Figure 3: Further simulation results for RD(T ) under the null hypothesis of no direct effect, β = 0.
The top row shows RD(T ) under block randomization and the bottom row shows RD(T ) under
cluster randomization. The left column shows results under different values of the variance of
individual-level susceptibility ηij and infectiousness ξij . The middle column shows how RD(T )
changes with the mean value of infectiousness ξij . The right column shows results under different
distributions for the cluster-level observation time Ti.
parameter values, simulation results show that the magnitude of RD(T ) changes substantially de-
pending on the specific study design and epidemiologic characteristics. In the Appendix we present
a simulation study exploring the properties of RD(T ) when β 6= 0.
4 Discussion
Greenwood and Yule [1915] proposed three conditions for making valid inferences about the effect of
a vaccine: 1) “The persons must be, in all material respects, alike”; 2) “The effective exposure to the
disease must be identical in the case of inoculated and uninoculated persons”; and 3) “The criteria
of the fact of inoculation and of the fact of the disease having occurred must be independent”.
Randomization ensures that conditions 1 and 3 are satisfied on average [Rothman et al., 2008,
Greenland and Robins, 1986, Halloran et al., 2010]. In this paper, we have shown that under
certain randomization designs, the risk difference defined as the “direct effect” by Hudgens and
Halloran [2008] compares individual infection outcomes in a way that ensures condition 2 does not
hold: treated and untreated subjects experience differential exposure to infectiousness, and the risk
difference RDij(t) is subject to confounding.
Though the proofs of Propositions 1-3 are technical, a heuristic explanation provides useful
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intuition.
1. Under Bernoulli randomization, treated and untreated subjects are exposed to the same
number of treated individuals on average.
2. Under block randomization, treated subjects are exposed to fewer treated individuals (mi−1)
than untreated subjects (mi).
3. Under cluster randomization, treated subjects are exposed to more treated individuals (ni−1)
than untreated subjects (0).
Therefore when the null hypothesis of β = 0 is true and an infectiousness effect exists (γ 6=
0), treated and untreated subjects under block and cluster randomization experience differential
exposure to infectiousness that depends on the sign of γ. These results apply to individuals within
clusters, and hold for any number of clusters. Similarly, odds and risk ratios computed by averaging
individual outcomes may be subject to the same biases [e.g. Morozova et al., 2018].
Our main results investigate the risk difference under the null hypothesis β = 0 because this
case is analytically tractable. Some real-world interventions may have this feature; for example,
transmission-blocking vaccines [Kaslow, 2002, Delrieu et al., 2015] have negligible direct effect, but
may be effective in reducing infectiousness of infected individuals. The results may apply in cases
where the true individual effect β is nonzero: because Y ij(t,xi) is a continuous function of β, there
may exist an interval around β 6= 0 in which the risk difference is “biased across the null” hypothesis
of no direct effect under some designs. In particular, under block randomization, a vaccine that both
helps prevent infection in each person who receives it (β < 0) and helps prevent transmission upon
infection (γ < 0) can nevertheless exhibit RD(t) > 0. When the risk difference RD(t) is interpreted
as a causal parameter, investigators may conclude that an effective intervention is harmful to the
individuals who receive it because its “direct effect” is positive. Simulation results in the Appendix
explore this region of sign mismatch between RD(t) and β 6= 0.
Researchers who wish to avoid the pathologies of the risk difference in a randomized trial have
three basic options. First, Proposition 1 shows that changing the randomization design to Bernoulli
allocation within clusters breaks the dependence between xij and xi(j). Then the conditional
probability Pr(Xi(j) = xi(j)|xij = x) in (3) becomes the marginal probability Pr(Xi(j) = xi(j)),
and the risk difference averages individualistic effects. Second, researchers may target a a marginal
estimand that does not condition on the assigned treatment, as VanderWeele and Tchetgen [2011]
and Sa¨vje et al. [2017] recommend. Third, when structural assumptions are warranted and enough
data are available, researchers may choose to fit a structural model similar to (1) [Rhodes et al.,
1996, Auranen et al., 2000, Cauchemez et al., 2006, Kenah, 2014].
Finally, we have focused here on three idealized randomization designs that are employed in
real-world intervention trials. Non-randomized (i.e. pragmatic, or observational) studies of inter-
ventions or risk factors for infection in clusters occupy an uncertain middle ground. Even when
the intervention or covariate of interest is unrelated to other baseline confounders and indepen-
dent of the potential infection outcomes, it may be unreasonable to assume that it is distributed
independently at random within clusters, as it would be under Bernoulli randomization. Likewise,
strict negative or positive correlation in covariate values, of the kind induced by block and cluster
randomization respectively, seems implausible. When any dependence exists in the distribution of
treatment in an observational study, regression adjustment or stratification on baseline covariates
may not be sufficient to ensure exchangeability of subjects with respect to infection exposure during
the study. Depending on the distribution of treatment, the relationship between the direction or
sign of marginal contrasts and the true direct effect may be difficult to predict.
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A Proof of Proposition 3
The proof of Proposition 3 proceeds in the same way as the proof of Proposition 2 in the main text.
We first state a preliminary lemma similar to Lemma 2.
Lemma 3. Let x1i = (1, . . . , 1) and x
0
i = (0, . . . , 0). Then if If γ < 0 then Y ij(t,x
1
i ) < Y ij(t,x
0
i );
if γ = 0 then Y ij(t,x
1
i ) = Y ij(t,x
0
i ); and if γ > 0 then Y ij(t,x
1
i ) > Y ij(t,x
0
i ).
Proof of Lemma 3. Define the vectors of stochastic potential outcomes Yi(t,x
1
i ) and Yi(t,x
0
i ), and
construct the coupled outcomes Y˜1i (t) and Y˜
0
i (t) under treatments x
1
i and x
0
i respectively, in the
same way as in the proof of Lemma 2. The case γ = 0 is the same as in the proof of Lemma 2, and
so Yij(t,x
1
i ) is equal in distribution to Yij(t,x
0
i ) for all t. When γ < 0, note that Y˜
1
ij(t) ≤ Y˜ 0ij(t) for
all t if and only if T˜ 1ij ≥ T˜ 0ij . Suppose without loss of generality that subjects are relabeled in order
of their infection in the constructed process, so the lth infection occurs in subject l, vl = l. The
waiting time from infection of subject l − 1 to infection of l has distribution function
Fl(w) = 1− exp
−w∑
a∈Sl
eηia
α+∑
b∈Il
eγx
1
ib+ξib

< 1− exp
−w∑
a∈Sl
eηia
α+∑
b∈Il
eξib

= 1− exp
−w∑
a∈Sl
eηia
α+∑
b∈Il
eγx
0
ib+ξib

= Gl(w)
(15)
for all w. Therefore F−1l (Ul) > G
−1
l (Ul) by monotonicity of Fl(w) and Gl(w), so the constructed
infection times are
T˜ 1ij =
j∑
l=1
W˜ 1l =
j∑
l=1
F−1l (Ul)
>
j∑
l=1
G−1l (Ul) =
j∑
l=1
W˜ 0l = T˜
0
ij
(16)
where we interpret an empty sum to be equal to zero. Therefore T˜ 1ij ≥ T˜ 0ij and hence Pr(Y˜ 1ij(t) ≤
Y˜ 0ij(t)) = 1. By Lemma 1, Yij(t,x
0) strictly stochastically dominates Y 0ij(t,x
1) for all t > 0. It
follows that the expected values of the potential infection outcomes obey Y ij(t,x
1) < Y ij(t,x
0).
The case of γ > 0 is the same as for γ < 0, with inequalities switched.
With this result, we can prove Proposition 3 directly.
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Proof of Proposition 3. Again let x1i = (1, . . . , 1) and x
0
i = (0, . . . , 0). Under cluster randomization,
RDij(T ) =
∑
z∈Xni−1
Y ij(T , 1, z) Pr(Xi(j) = z|xij = 1)− Y ij(T , 0, z) Pr(Xi(j) = z|xij = 0)
=
∑
z∈Xni−1
Y ij(T , 1, z)1{|z| = ni − 1} − Y ij(T , 0, z)1{|z| = 0}
= Y ij(T ,x1i )− Y ij(T ,x0i ).
(17)
Therefore, RDij(T ) can be expressed as a contrast between the outcome of j when all subjects are
treated, versus when no subjects are treated. This contrast has sign given by Lemma 3, and the
result follows.
B Simulation study
B.1 Additional simulation details
The hazard of infection takes the form given in (1) of the main text, where β = 0 and γ takes a
specified value. Unless otherwise noted, the exogenous force of infection is α = 0.01, the individual
susceptibility coefficients ηij are independent Normal(µη, σ
2
η) and infectiousness coefficients ξij are
independent Normal(µξ, σ
2
ξ ), all individuals were assumed uninfected at baseline Yij(0) = 0, the
cluster size ni is 2+Poisson(2), and the observation time is T = 10. Table 1 summarizes the values
of all simulation parameters.
The following estimators identify the population-level effect RD(T ) under the various random-
ization designs. These estimator were used to compute the population average risk difference in
the simulation study. Under Bernoulli randomization, define
R̂D(T ) = 1
N
N∑
i=1
1
ni
ni∑
j=1
yijxij
p
− yij(1− xij)
1− p .
Under block randomization, define
R̂D(T ) = 1
N
N∑
i=1
∑ni
j=1 yijxij∑ni
j=1 xij
−
∑ni
j=1 yij(1− xij)∑ni
j=1(1− xij)
.
Under cluster randomization, let Si = 1 when the cluster is assigned treatment, and let Si = 0
otherwise. Define
R̂D(T ) =
∑N
i=1
Si
ni
∑ni
j=1 yij∑N
i=1 Si
−
∑N
i=1
(1−Si)
ni
∑ni
j=1 yij∑N
i=1(1− Si)
.
B.2 Additional simulation results
Figures 2 and 3 in the paper illustrate the behavior of the population average risk difference RD(T )
as a function of the indirect (infectiousness) effect γ under the null hypothesis of β = 0. In this
section we provide the results of the simulations for a range of values of direct susceptibility effect,
−2 < β < 2. In Figures 4 - 12, the top row shows a heat map of the population average risk
difference as a function of the susceptibility effect β (horizontal axis) and infectiousness effect γ
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Table 1: Summary of simulation parameters
Notation Parameter Value
β direct (susceptibility) effect of x 0 in Figures 2 and 3 of the main text
[-2 ; 2] in Figures 4 - 12
γ infectiousness effect of x [-2 ; 2]
∆β, ∆γ increment size for β and γ 0.1
α external force of infection 0.01
η individual-level susceptibility unless otherwise noted, ηij ∼ N(0, 0.12)
ξ individual-level infectiousness unless otherwise noted, ξij ∼ N(0, 0.12)
ni size of cluster i unless otherwise noted, ni ∼ 2 + Pois(2)
T observation time unless otherwise noted, T = 10
Y (0) infections at t = 0 Yij(0) = 0, j = 1, . . . , ni; i = 1, . . . , N
p treatment assignment probability under 0.5
Bernoulli and cluster randomization
mi number treated per cluster bni/2c
under block randomization
N number of clusters 1000
Ns number of simulations 100 - 2000
per combination of parameter values
(vertical axis). Blue color corresponds to negative values of RD(T ), and red color to positive values.
The risk difference is a direction-unbiased estimate of the direct effect if red color is on the right of
the vertical line that corresponds to β = 0, and blue color is on the left of this line. The bottom
row of Figures 4 - 12 shows the regions in the two-dimensional (β; γ) space, where the sign of the
risk difference is opposite that of β. These regions are colored black.
Figures 4 - 6 correspond to the same study designs as those used to produce Figure 2 in the
paper. The risk difference is direction-unbiased under Bernoulli randomization, while under block
and cluster randomization the risk difference exhibits direction bias in some regions of the (β; γ)
space. Under block randomization, the sign of population average risk difference is opposite that
of β when β and γ have the same sign, and γ is more extreme than β. Under cluster random-
ization, direction bias of the risk difference appears in the regions, where β and γ have opposite
signs. Figure 6 shows that under cluster randomization and a given set of simulation parameters,
when β < 0, the region of direction bias is very small. Absence of black regions in the upper left
quadrants of the bottom row plots in Figure 6 is an artifact of the chosen range of values of β,
as well as the step size. The region of direction bias gets smaller with the increase of the cluster size.
The magnitude of RD(T ) under the null of β = 0 is not necessarily related to the size of the
direction-bias region when β 6= 0. Figure 2 in the main text shows that under the null, cluster
randomization results in a larger size of the bias compared to block randomization. At the same
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Figure 4: Population average RD under Bernoulli randomization and different cluster sizes.
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Figure 5: Population average RD under block randomization and different cluster sizes.
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Figure 6: Population average RD under cluster randomization and different cluster sizes.
time, the region in the (β; γ) space where the risk difference exhibits direction bias is larger under
block compared to cluster randomization (all other thing being equal). This happens because under
cluster randomization the the risk difference changes substantially more rapidly in response to one
unit change in the value of β compared to the risk difference under block randomization.
Figures 7 - 8 correspond to the same study designs as the left column of Figure 3 in the paper.
The region of direction bias increases with the increase of variance of untreated individual-level
susceptibility (η) and infectiousness (ξ).
Figures 9 - 10 correspond to the same study designs as the middle column of Figure 3 in the
main text. Under the block randomization the region of direction bias gets smaller as the mean
untreated within-cluster infectiousness decreases (Figure 9). However, under cluster randomization
this relationship is non-monotonic: the region of direction bias is very small for extreme (small or
large) values of average untreated within-cluster infectiousness, and largest when the mean of ξ is
somewhere in the middle (Figure 10).
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Figure 7: Population average RD under block randomization and different variance of individual-
level susceptibility (η) and infectiousness (ξ).
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Figure 8: Population average RD under cluster randomization and different variance of individual-
level susceptibility (η) and infectiousness (ξ).
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Figure 9: Population average RD under block randomization and different average individual-level
infectiousness (ξ).
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Figure 10: Population average RD under cluster randomization and different average individual-
level infectiousness (ξ).
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Figure 11: Population average RD under block randomization and different observation time.
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Figure 12: Population average RD under cluster randomization and different observation time.
Figures 11 - 12 correspond to the same study designs as the right column of Figure 3 in the paper.
The region where the risk difference exhibits direction bias as an estimate of direct susceptibility
effect increases with the observation time under block randomization (Figure 11), but decreases
under cluster randomization (Figure 12).
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